AVITA Medical (RCEL) said Monday that the US Food and Drug Administration has approved its premarket approval supplement for Recell Go Mini.
The Recell Go Mini disposable cartridge, which is a line extension of the Recell Go system, was designed specifically to treat smaller wounds of up to 480 square centimeters, the company said.
AVITA said the rollout will start with trauma and burn centers that treat smaller wounds during Q1 2025.
The shares of AVITA Medical rose 4.3% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.